HLA class I antigen and beta 2 microglobulin are negative in melanomas with no extrascleral extension and liver metastases and weak in melanomas with extrascleral extension and are positive in melanomas with liver metastases. HLA expression is independent of the conventional markers in uveal melanoma.
Antigen-processing molecules are decreased in orbital melanomas with increasing aggressiveness. This could have important implications for immunotherapy. This preliminary observation deserves further investigation, which may shed more light on the immune escape mechanisms of this tumor and thus make possible novel therapeutic strategies.
Major histocompatibility antigens (MHC) play a crucial role in the recognition of tumor cells by the immune system. There is not much information on the role of MHC molecule expression in primary orbital melanomas. In the present study, the authors examined the expression of human leukocyte antigen (HLA) class I, beta(2)-microglobulin (beta(2)-m) and HLA class II antigens in primary orbital melanoma and correlated this with the clinical and pathological findings. HLA class I antigen, beta(2)-m and HLA class II antigen expression were evaluated immunohistochemically in three primary orbital melanomas and correlated with cell type and metastasis. Immunohistochemistry showed heterogeneous expression of HLA class I, beta(2)-m and HLA class II antigen in two cases with no liver metastasis and negative expression in one case with liver metastasis. This preliminary observation deserves further investigation, which may shed more light on the immune escape mechanisms of this tumor and thus make possible novel therapeutic strategies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.